Diptomit Biswas, Sara Benson, Aidan Matunis, Gebremichal Gebretsadik, Adam Wertz, Ben J StPierre, Nathan Schacht, Yue Yan, Hanna Y Gebremichael, Pak Kin Wong, Anthony D Baughn, Scott H Medina
{"title":"抗结核宿主防御肽的人工智能先导挖掘。","authors":"Diptomit Biswas, Sara Benson, Aidan Matunis, Gebremichal Gebretsadik, Adam Wertz, Ben J StPierre, Nathan Schacht, Yue Yan, Hanna Y Gebremichael, Pak Kin Wong, Anthony D Baughn, Scott H Medina","doi":"10.1021/acs.biomac.5c00244","DOIUrl":null,"url":null,"abstract":"<p><p>Identifying host defense peptides (HDPs) that are effective against drug-resistant infections is challenging due to their vast sequence space. Artificial intelligence (AI)-guided design can accelerate HDP discovery, but it traditionally requires large data sets to operationalize. We report an AI workflow that utilizes limited data sets (∼100 peptides) to uncover potent, selective, and safe HDPs by informing selection through lead candidate mutational scanning. This approach, referred to as Lead Informed Machine Interrogation of Therapeutic Sequences (LIMITS), is applied against the exemplary pathogen <i>Mycobacterium tuberculosis</i>. Experimental validation of predicted sequences shows nearly an order of magnitude improvement in potency, selectivity, and safety, relative to the initial template. Post hoc analysis suggests sequence length may be a unique and underappreciated driver of antitubercular HDP activity. These results demonstrate that, with continued development, the LIMITS approach can identify selective HDPs under data-limited conditions and elucidate structure-function-performance relationships previously hidden in biologic complexity.</p>","PeriodicalId":30,"journal":{"name":"Biomacromolecules","volume":"26 5","pages":"3167-3179"},"PeriodicalIF":5.5000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076502/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lead Informed Artificial Intelligence Mining of Antitubercular Host Defense Peptides.\",\"authors\":\"Diptomit Biswas, Sara Benson, Aidan Matunis, Gebremichal Gebretsadik, Adam Wertz, Ben J StPierre, Nathan Schacht, Yue Yan, Hanna Y Gebremichael, Pak Kin Wong, Anthony D Baughn, Scott H Medina\",\"doi\":\"10.1021/acs.biomac.5c00244\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Identifying host defense peptides (HDPs) that are effective against drug-resistant infections is challenging due to their vast sequence space. Artificial intelligence (AI)-guided design can accelerate HDP discovery, but it traditionally requires large data sets to operationalize. We report an AI workflow that utilizes limited data sets (∼100 peptides) to uncover potent, selective, and safe HDPs by informing selection through lead candidate mutational scanning. This approach, referred to as Lead Informed Machine Interrogation of Therapeutic Sequences (LIMITS), is applied against the exemplary pathogen <i>Mycobacterium tuberculosis</i>. Experimental validation of predicted sequences shows nearly an order of magnitude improvement in potency, selectivity, and safety, relative to the initial template. Post hoc analysis suggests sequence length may be a unique and underappreciated driver of antitubercular HDP activity. These results demonstrate that, with continued development, the LIMITS approach can identify selective HDPs under data-limited conditions and elucidate structure-function-performance relationships previously hidden in biologic complexity.</p>\",\"PeriodicalId\":30,\"journal\":{\"name\":\"Biomacromolecules\",\"volume\":\"26 5\",\"pages\":\"3167-3179\"},\"PeriodicalIF\":5.5000,\"publicationDate\":\"2025-05-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076502/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomacromolecules\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.biomac.5c00244\",\"RegionNum\":2,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomacromolecules","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1021/acs.biomac.5c00244","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Lead Informed Artificial Intelligence Mining of Antitubercular Host Defense Peptides.
Identifying host defense peptides (HDPs) that are effective against drug-resistant infections is challenging due to their vast sequence space. Artificial intelligence (AI)-guided design can accelerate HDP discovery, but it traditionally requires large data sets to operationalize. We report an AI workflow that utilizes limited data sets (∼100 peptides) to uncover potent, selective, and safe HDPs by informing selection through lead candidate mutational scanning. This approach, referred to as Lead Informed Machine Interrogation of Therapeutic Sequences (LIMITS), is applied against the exemplary pathogen Mycobacterium tuberculosis. Experimental validation of predicted sequences shows nearly an order of magnitude improvement in potency, selectivity, and safety, relative to the initial template. Post hoc analysis suggests sequence length may be a unique and underappreciated driver of antitubercular HDP activity. These results demonstrate that, with continued development, the LIMITS approach can identify selective HDPs under data-limited conditions and elucidate structure-function-performance relationships previously hidden in biologic complexity.
期刊介绍:
Biomacromolecules is a leading forum for the dissemination of cutting-edge research at the interface of polymer science and biology. Submissions to Biomacromolecules should contain strong elements of innovation in terms of macromolecular design, synthesis and characterization, or in the application of polymer materials to biology and medicine.
Topics covered by Biomacromolecules include, but are not exclusively limited to: sustainable polymers, polymers based on natural and renewable resources, degradable polymers, polymer conjugates, polymeric drugs, polymers in biocatalysis, biomacromolecular assembly, biomimetic polymers, polymer-biomineral hybrids, biomimetic-polymer processing, polymer recycling, bioactive polymer surfaces, original polymer design for biomedical applications such as immunotherapy, drug delivery, gene delivery, antimicrobial applications, diagnostic imaging and biosensing, polymers in tissue engineering and regenerative medicine, polymeric scaffolds and hydrogels for cell culture and delivery.